Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. Financials
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  05/16 04:00:00 pm EDT
136.26 USD   -1.20%
05/13MODERNA, INC. Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K/A)
AQ
05/13SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
05/13KHF Welcomes the African Medicines Agency Treaty Cabinet Approval
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 6 51841 340102 97654 855--
Enterprise Value (EV)1 5 54836 84292 84836 33332 19229 618
P/E ratio -12,6x-53,3x8,98x5,08x17,5x39,7x
Yield ------
Capitalization / Revenue 108x51,5x5,58x2,49x5,55x7,78x
EV / Revenue 92,1x45,9x5,03x1,65x3,26x4,20x
EV / EBITDA -10,8x-50,3x6,86x2,65x7,55x9,62x
Price to Book 6,14x16,3x7,24x2,19x1,83x1,66x
Nbr of stocks (in thousands) 333 250395 710405 450397 760--
Reference price (USD) 19,6104254138138138
Announcement Date 02/26/202002/25/202102/24/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 60,280318 47122 0229 8857 046
EBITDA1 -515-73213 52813 7134 2633 080
Operating profit (EBIT)1 -546-76313 29613 6474 2331 770
Operating Margin -906%-95,0%72,0%62,0%42,8%25,1%
Pre-Tax Profit (EBT)1 -515-74513 28513 6104 2021 576
Net income1 -514-74712 20211 4743 3511 554
Net margin -854%-93,0%66,1%52,1%33,9%22,0%
EPS2 -1,55-1,9628,327,27,893,47
Dividend per Share2 ------
Announcement Date 02/26/202002/25/202102/24/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 4 9697 2116 0664 1055 9326 128
EBITDA -5 488----
Operating profit (EBIT)1 3 5585 4104 2272 2263 5903 616
Operating Margin 71,6%75,0%69,7%54,2%60,5%59,0%
Pre-Tax Profit (EBT)1 3 5525 4104 2292 1503 7293 680
Net income1 3 3334 8683 6571 9142 9982 865
Net margin 67,1%67,5%60,3%46,6%50,5%46,8%
EPS2 7,7011,38,584,767,136,67
Dividend per Share ------
Announcement Date 11/04/202102/24/202205/04/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 9714 49810 12818 52222 66325 237
Leverage (Debt / EBITDA) 1,89x6,15x-0,75x-1,35x-5,32x-8,19x
Free Cash Flow1 -4911 96013 3368 5014 8162 573
ROE (Net Profit / Equities) -38,0%-40,0%146%58,4%10,9%3,79%
Shareholders' equity1 1 3531 8688 35319 63130 69740 987
ROA (Net Profit / Asset) -28,9%-16,7%76,2%40,4%6,29%0,83%
Assets1 1 7764 46316 00328 39353 305187 800
Book Value Per Share2 3,196,4235,163,175,383,1
Cash Flow per Share2 -5,3231,619,96,601,36
Capex1 31,667,4284703478396
Capex / Sales 52,4%8,40%1,54%3,19%4,83%5,63%
Announcement Date 02/26/202002/25/202102/24/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Analysis
Pfizer's $11.6 billion Biohaven buy could spark more biotech deals
Key data
Capitalization (USD) 54 855 014 989
Net sales (USD) 18 471 000 000
Number of employees 2 700
Sales / Employee (USD) 6 841 111
Free-Float 90,6%
Free-Float capitalization (USD) 49 679 895 488
Avg. Exchange 20 sessions (USD) 923 330 319
Average Daily Capital Traded 1,68%
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA